Stock EURO EURO-MED LABORATORIES PHIL., INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Euro-Med Laboratories Phil., Inc.

Equities

EURO

PHY2352T1098

Pharmaceuticals

End-of-day quote Philippines S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
0.73 PHP -6.41% Intraday chart for Euro-Med Laboratories Phil., Inc. -1.35% -2.67%
Apr. 15 Euro-Med Laboratories Phil., Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Euro-Med Laboratories Phil., Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 6,991 6,579 9,622 5,757 3,578 3,084
Enterprise Value (EV) 1 9,194 9,156 12,481 8,450 6,452 6,040
P/E ratio 18.9 x 17.8 x 46.8 x 34.1 x 17.9 x 10.7 x
Yield 4.12% 3.13% 0.64% 1.43% 4.02% -
Capitalization / Revenue 1.34 x 1.16 x 2.51 x 1.6 x 0.85 x 0.59 x
EV / Revenue 1.77 x 1.61 x 3.26 x 2.36 x 1.53 x 1.15 x
EV / EBITDA 10.4 x 9.14 x 16.4 x 13.2 x 9.72 x 6.78 x
EV / FCF 84.2 x 536 x -155 x 68.4 x -113 x 2,447 x
FCF Yield 1.19% 0.19% -0.65% 1.46% -0.89% 0.04%
Price to Book 1.31 x 1.21 x 1.77 x 1.02 x 0.63 x 0.53 x
Nbr of stocks (in thousands) 4,112,141 4,112,141 4,112,141 4,112,141 4,112,141 4,112,141
Reference price 2 1.700 1.600 2.340 1.400 0.8700 0.7500
Announcement Date 4/15/19 6/29/20 4/30/21 5/10/22 4/18/23 4/15/24
1PHP in Million2PHP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 5,208 5,688 3,829 3,587 4,224 5,264
EBITDA 1 885.5 1,002 763 639 664.1 890.7
EBIT 1 661.6 760.9 540.7 411.1 440.4 652.6
Operating Margin 12.7% 13.38% 14.12% 11.46% 10.43% 12.4%
Earnings before Tax (EBT) 1 536.9 557.1 305 231.4 280.3 398.4
Net income 1 373.9 388.9 210.1 169 199.9 289.9
Net margin 7.18% 6.84% 5.49% 4.71% 4.73% 5.51%
EPS 2 0.0900 0.0900 0.0500 0.0411 0.0486 0.0700
Free Cash Flow 1 109.2 17.09 -80.75 123.6 -57.12 2.469
FCF margin 2.1% 0.3% -2.11% 3.45% -1.35% 0.05%
FCF Conversion (EBITDA) 12.33% 1.71% - 19.34% - 0.28%
FCF Conversion (Net income) 29.19% 4.39% - 73.12% - 0.85%
Dividend per Share 2 0.0700 0.0500 0.0150 0.0200 0.0350 -
Announcement Date 4/15/19 6/29/20 4/30/21 5/10/22 4/18/23 4/15/24
1PHP in Million2PHP
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 2,203 2,577 2,859 2,693 2,874 2,956
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 2.488 x 2.572 x 3.747 x 4.215 x 4.328 x 3.318 x
Free Cash Flow 1 109 17.1 -80.7 124 -57.1 2.47
ROE (net income / shareholders' equity) 7.1% 7.2% 3.85% 3.05% 3.52% 5.02%
ROA (Net income/ Total Assets) 4.43% 4.75% 3.31% 2.6% 2.79% 3.92%
Assets 1 8,446 8,181 6,343 6,501 7,171 7,402
Book Value Per Share 2 1.300 1.330 1.320 1.370 1.390 1.420
Cash Flow per Share 2 0.2500 0.2700 0.1200 0.1300 0.1500 0.2100
Capex 1 682 582 451 286 88.9 292
Capex / Sales 13.1% 10.24% 11.77% 7.96% 2.1% 5.54%
Announcement Date 4/15/19 6/29/20 4/30/21 5/10/22 4/18/23 4/15/24
1PHP in Million2PHP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
EURO-MED LABORATORIES PHIL., INC. Stock Euro-Med Laboratories Phil., Inc.
-2.67% 55.52M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+20.81% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+13.30% 14.09B
CIPLA LIMITED Stock Cipla Limited
+12.97% 13.64B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+39.74% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. EURO Stock
  4. Financials Euro-Med Laboratories Phil., Inc.